Anti-Human LOXL2 Recombinant Antibody (Simtuzumab) (CAT#: TAB-890)

Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 Effects of Simtuzumab on normal myofibroblast differentiation and invasion.

Figure 1 Effects of Simtuzumab on normal myofibroblast differentiation and invasion.

Fibroblast cultures derived from normal lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.

Inhib

Figure 2 Effects of Simtuzumab on IPF myofibroblast differentiation and invasion.

Figure 2 Effects of Simtuzumab on IPF myofibroblast differentiation and invasion.

Fibroblast cultures derived from IPF lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.

Agonist

Figure 3 Simtuzumab accelerates cell differentiation in vitro.

Figure 3 Simtuzumab accelerates cell differentiation in vitro.

Explanted lung cells from normal and IPF lung samples were treated with anti-LOXL2 (50 μg/ml), or IgG for 26 days. Media and treatments were replaced 2x/week until day 26.

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • undefined
  • Derivation
  • Humanized
  • Type
  • IgG4 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Inhib, Agonist
  • CAS
  • 1318075-13-6
  • Generic Name
  • Simtuzumab
  • MW
  • 147.5 kDa
  • Related Disease
  • Myelofibrosis

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

Applications

  • Application Notes
  • The LOXL2 ADCC antibody has been reported in applications of Inhibition, Agonist.
    Inhib: 1, 10, and 50 μg/ml.
    Agonist: 50 μg/ml.

Target

  • Alternative Names
  • Simtuzumab;1318075-13-6;AB0024;GS-6624;LOXL2;lysyl oxidase-like 2;lysyl oxidase homolog 2;WS9 14;lysyl oxidase related 2;lysyl oxidase-like protein 2;lysyl oxidase-related protein 2;lysyl oxidase-related protein WS9-14;LOR2;WS9-14;

Related Resources

  • Biosimilar Overview
Please refer to Simtuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Simtuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Simtuzumab"

Afuco™ Anti-LOXL2 ADCC Recombinant Antibody (Simtuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.

See other products for "LOXL2"

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-2075 Hi-Affi™ Recombinant Rabbit Anti-LOXL2 Monoclonal Antibody (DS2075AB) ICC/IF, FC, WB IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-890 Afuco™ Anti-LOXL2 ADCC Recombinant Antibody (Simtuzumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-890. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare